Earnings Update: Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

It's been a good week for Caplin Point Laboratories Limited (NSE:CAPLIPOINT) shareholders, because the company has just released its latest annual results, and the shares gained 8.0% to ₹2,010. It was a pretty mixed result, with revenues beating expectations to hit ₹20b. Statutory earnings fell 2.1% short of analyst forecasts, reaching ₹70.25 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Caplin Point Laboratories after the latest results.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

Taking into account the latest results, the current consensus from Caplin Point Laboratories' three analysts is for revenues of ₹22.3b in 2026. This would reflect a decent 9.7% increase on its revenue over the past 12 months. Per-share earnings are expected to climb 13% to ₹79.97. Before this earnings report, the analysts had been forecasting revenues of ₹22.3b and earnings per share (EPS) of ₹79.70 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

View our latest analysis for Caplin Point Laboratories

It will come as no surprise then, to learn that the consensus price target is largely unchanged at ₹2,472. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Caplin Point Laboratories, with the most bullish analyst valuing it at ₹2,512 and the most bearish at ₹2,396 per share. Still, with such a tight range of estimates, it suggeststhe analysts have a pretty good idea of what they think the company is worth.

Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Caplin Point Laboratories' revenue growth is expected to slow, with the forecast 9.7% annualised growth rate until the end of 2026 being well below the historical 16% p.a. growth over the last five years. Compare this to the 170 other companies in this industry with analyst coverage, which are forecast to grow their revenue at 10% per year. So it's pretty clear that, while Caplin Point Laboratories' revenue growth is expected to slow, it's expected to grow roughly in line with the industry.

The Bottom Line

The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. The consensus price target held steady at ₹2,472, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Caplin Point Laboratories going out to 2027, and you can see them free on our platform here.

We also provide an overview of the Caplin Point Laboratories Board and CEO remuneration and length of tenure at the company, and whether insiders have been buying the stock, here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.